▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #2896 by analyst upside · 2026-09-27
ONC
BeOne Medicines AG
Healthcare · Market Cap $41B · P/E 64.6x
ANALYST PRICE TARGET
+19.9%
implied upside to consensus target
Current Price $360.85
Consensus Target $432.8
Bull Target $528.0
Bear Target $370.0
Analysts Covering 28
ANALYST CONSENSUS - BUY
Strong Buy
7
Buy
20
Hold
1
Sell
0
52-Week Low $253.95
52-Week High $385.22
YTD Return +16.0%
FUNDAMENTALS
Market Cap $41B
P/E Ratio (TTM) 64.6x
Forward P/E 35.0x
EPS (TTM) $5.59
PEG Ratio 0.76
Dividend Yield N/A
Revenue (TTM) $6.1B
Profit Margin 10.7%
52-WEEK RANGE
52-Week Low $253.95
52-Week High $385.22
Current Price $360.85
Bear Target $370.0
Bull Target $528.0
● Now $360.85 ● Target $432.8
TRADING DATA
Avg Volume 388K
YTD Return +16.0%
Analyst Count 28
Consensus Buy
Upside to Target +19.9%
Last Updated 2026-09-27

ANALYST SUMMARY

BeOne Medicines AG (ONC) is currently trading at $360.85 with a Wall Street consensus price target of $432.8, implying potential upside of 19.9% over the next 12 months. 28 analysts currently cover ONC, with a consensus rating of Buy - 96% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $528.0, while the most cautious has a target of $370.0.

ONC operates in the Healthcare sector with a market capitalisation of $41B. The stock is up 16.0% year-to-date and is currently trading near the upper end of its 52-week range of $253.95 – $385.22.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

TEVA +12.3%
Teva Pharmaceutical Industries Limited
$46B · P/E 65.3x · Buy
GALDY +26.2%
Galderma Group AG
$46B · P/E 54.0x · Buy
VEEV +5.9%
Veeva Systems Inc.
$45B · P/E 46.1x · Buy
ALC +31.0%
Alcon Inc.
$31B · P/E 49.2x · Buy
ALNY +45.1%
Alnylam Pharmaceuticals, Inc.
$34B · P/E 44.7x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for ONC, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Barclays - Reiterated
Overweight → Overweight 2026-09-10 Building track record
TD Cowen - Reiterated
Buy → Buy 2026-08-06 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-08-06 Building track record
Truist Securities - Reiterated
Buy → Buy 2026-08-06 Building track record
Guggenheim - Reiterated
Buy → Buy 2026-08-06 62% win rate (8 calls)
Barclays - Reiterated
Overweight → Overweight 2026-08-06 Building track record
Citizens - Reiterated
Market Outperform → Market Outperform 2026-08-06 Building track record
JP Morgan - Reiterated
Overweight → Overweight 2026-07-23 43% win rate (7 calls)
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
69
out of 100
Coverage depth
26/30
Consensus clarity
21/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →